Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Non-current Assets to Total Assets Ratio for the year ending December 31, 2023: 0.01

Rallybio Corp Non-current Assets to Total Assets Ratio is 0.01 for the year ending December 31, 2023, a 38.11% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Rallybio Corp Non-current Assets to Total Assets Ratio for the year ending December 31, 2022 was 0.01, a -27.96% change year over year.
Rallybio Corp Non-current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.01, a 71.64% change year over year.
Rallybio Corp Non-current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.00, a -86.76% change year over year.
Rallybio Corp Non-current Assets to Total Assets Ratio for the year ending December 31, 2019 was 0.03.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends